Kidney International Reports最新文献

{"title":"Bringing a Systems Approach to Living Donor Kidney Transplantation","authors":"Anna Horton ,&nbsp;Katya Loban ,&nbsp;Peter Nugus ,&nbsp;Marie-Chantal Fortin ,&nbsp;Lakshman Gunaratnam ,&nbsp;Greg Knoll ,&nbsp;Istvan Mucsi ,&nbsp;Prosanto Chaudhury ,&nbsp;David Landsberg ,&nbsp;Michel R. Pâquet ,&nbsp;Marcelo Cantarovich ,&nbsp;Shaifali Sandal","doi":"10.1016/j.ekir.2024.07.014","DOIUrl":"10.1016/j.ekir.2024.07.014","url":null,"abstract":"<div><h3>Introduction</h3><div>Living donor kidney transplantation (LDKT) is the best treatment option for patients with kidney failure. Efforts to increase LDKT have focused on microlevel interventions and the need for systems thinking has been highlighted. We aimed to identify and compare health system–level attributes and processes that are facilitators and barriers to LDKT.</div></div><div><h3>Methods</h3><div>We conducted a qualitative comparative case study analysis of 3 Canadian provincial health care systems with variable LDKT performance (Quebec: low, Ontario: moderate-high, British Columbia: high). Data collection entailed semistructured interviews (<em>n</em> = 91), document review (<em>n</em> = 97) and focus groups (<em>n</em> = 5 with 40 participants), analyzed using inductive thematic analysis.</div></div><div><h3>Results</h3><div>Our findings showed a strong relationship between the degree of centralized coordination between governing organizations and the capacity to deliver LDKT as follows. (i) macro-level coordination between governing organizations in British Columbia and Ontario increased capacities, whereas Québec was seen as decentralized with little formal coordination; (ii) a higher degree of centralized coordination facilitated more effective resource deployment in the form of human resources and initiatives in British Columbia and Ontario, whereas in Québec resource deployment relied on hospital budgets leading to competition for resources and reduced capacity of initiatives; (iii) informal resource sharing through strong communities of practice and local champions facilitated LDKT in Ontario and British Columbia and was limited in Québec.</div></div><div><h3>Conclusion</h3><div>Our findings suggest that interventions that account for full-system function, particularly macro-level coordination between governing organizations can improve LDKT delivery. Findings may be used to guide structured organizational change toward increasing LDKT and mitigating the global burden of kidney failure.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 10","pages":"Pages 2915-2926"},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141843234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Climate Change, Heat Stress, and Kidney Disease–Associated Mortality and Health Care Utilization","authors":"Naresh Kumar ,&nbsp;Venkata Madhavi Latha Telagarapu ,&nbsp;Alessia Fornoni","doi":"10.1016/j.ekir.2024.08.018","DOIUrl":"10.1016/j.ekir.2024.08.018","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 10","pages":"Pages 2844-2847"},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary Soluble CD163: A Novel Biomarker Suggests Who Should Receive Glucocorticoids in IgA Nephropathy","authors":"Guisen Li ,&nbsp;Susan J. Thanabalasingam","doi":"10.1016/j.ekir.2024.08.011","DOIUrl":"10.1016/j.ekir.2024.08.011","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 10","pages":"Pages 2848-2850"},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased Blood-Brain Barrier Permeability and Cognitive Impairment in Patients With ESKD","authors":"Mickaël Bobot ,&nbsp;Eric Guedj ,&nbsp;Noémie Resseguier ,&nbsp;Julien Faraut ,&nbsp;Philippe Garrigue ,&nbsp;Vincent Nail ,&nbsp;Guillaume Hache ,&nbsp;Sandra Gonzalez ,&nbsp;Nathalie McKay ,&nbsp;Romain Vial ,&nbsp;Dammar Bouchouareb ,&nbsp;Guillaume Lano ,&nbsp;Noémie Jourde-Chiche ,&nbsp;Ariane Duval-Sabatier ,&nbsp;Fabrice Guilaume ,&nbsp;Benjamin Guillet ,&nbsp;Stéphane Burtey","doi":"10.1016/j.ekir.2024.07.021","DOIUrl":"10.1016/j.ekir.2024.07.021","url":null,"abstract":"<div><h3>Introduction</h3><div>Chronic kidney disease (CKD) is associated with an increased risk of cognitive impairment. This cognitive impairment is associated with an increased permeability of blood-brain barrier (BBB) in rodents with CKD, linked to activation of aryl hydrocarbon receptor (AhR) by indoxyl sulphate (IS). The objective of the BREIN study was to confirm the increased BBB permeability in humans with CKD.</div></div><div><h3>Method</h3><div>The BREIN comparative study (NCT04328415) prospectively included patients with end-stage kidney disease (ESKD) and controls healthy volunteers matched in age, sex, and level of education to a patient. In all participants, BBB permeability was quantified by brain ^99mTc-DTPA SPECT/CT as a percentage of injected activity (% IA). A battery of neurocognitive tests was performed, and serum uremic toxins accumulation and AhR activation were assessed.</div></div><div><h3>Results</h3><div>Fifteen patients with ESKD and 14 healthy volunteers were analyzed. Patients with ESKD had higher BBB permeability compared to controls: 0.29 ± 0.07 versus 0.14 ± 0.06 %IA, <em>P</em> = 0.002. Patients with ESKD displayed lower Montreal Cognitive Assessment test (MoCA) score: 22.0 ± 5.0 versus 27.3 ± 2.8, <em>P</em> = 0.008; impaired short-term memory (doors test): 12.5 ± 3.4 versus 16.5 ± 3.4, <em>P</em> = 0.005; higher Beck depression score 8.1 ± 9.1 versus 2.7 ± 3.4, <em>P</em> = 0.046; and slightly more daily cognitive complaints: 42.5 ± 29.3 versus 29.8 ± 14.0 <em>P</em> = 0.060. Patients with ESKD displayed higher IS levels (86.1 ± 48.4 vs. 3.2 ± 1.7 μmol/l, <em>P</em> = 0.001) and AhR activating potential (37.7 ± 17.8% vs. 24.7 ± 10.4%, <em>P</em> = 0.027). BBB permeability was inversely correlated with MoCA score (<em>r</em> = −0.60, 95% confidence interval [−0.772 to −0.339], <em>P</em> = 0.001) in the overall population.</div></div><div><h3>Conclusion</h3><div>Patients with ESKD display an increased BBB permeability compared to matched healthy volunteers. Association with uremic toxins and cognitive impairment needs to be assessed in larger cohorts of patients.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 10","pages":"Pages 2988-2995"},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141849757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronaries, Calcium, and Kidney Consequences","authors":"Brian Rifkin ,&nbsp;Anthony Valeri","doi":"10.1016/j.ekir.2024.06.040","DOIUrl":"10.1016/j.ekir.2024.06.040","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 10","pages":"Pages 2839-2841"},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers of Kidney Disease Progression in ADPKD","authors":"Ahmad Ghanem ,&nbsp;Abdul Hamid Borghol ,&nbsp;Fadi George Munairdjy Debeh ,&nbsp;Stefan Paul ,&nbsp;Bassel AlKhatib ,&nbsp;Peter C. Harris ,&nbsp;Pranav S. Garimella ,&nbsp;Christian Hanna ,&nbsp;Timothy L. Kline ,&nbsp;Neera K. Dahl ,&nbsp;Fouad T. Chebib","doi":"10.1016/j.ekir.2024.07.012","DOIUrl":"10.1016/j.ekir.2024.07.012","url":null,"abstract":"<div><div>Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disorder and the fourth leading cause of kidney failure (KF) in adults. Characterized by a reduction in glomerular filtration rate (GFR) and increased kidney size, ADPKD exhibits significant variability in progression, highlighting the urgent need for reliable and predictive biomarkers to optimize management and treatment approaches. This review explores the roles of diverse biomarkers—including clinical, genetic, molecular, and imaging biomarkers—in evaluating disease progression and customizing treatments for ADPKD. Clinical biomarkers such as biological sex, the predicting renal outcome in polycystic kidney disease <strong>(</strong>PROPKD) score, and body mass index are shown to correlate with disease severity and progression. Genetic profiling, particularly distinguishing between truncating and non-truncating pathogenic variants in the <em>PKD1</em> gene, refines risk assessment and prognostic precision. Advancements in imaging significantly enhance our ability to assess disease severity. Height-adjusted total kidney volume (htTKV) and the Mayo imaging classification (MIC) are foundational, whereas newer imaging biomarkers, including texture analysis, total cyst number (TCN), cyst-parenchyma surface area (CPSA), total cyst volume (TCV), and cystic index, focus on detailed cyst characteristics to offer deeper insights. Molecular biomarkers (including serum and urinary markers) shed light on potential therapeutic targets that could predict disease trajectory. Despite these advancements, there is a pressing need for the development of response biomarkers in both the adult and pediatric populations, which can evaluate the biological efficacy of treatments. The holistic evaluation of these biomarkers not only deepens our understanding of kidney disease progression in ADPKD, but it also paves the way for personalized treatment strategies aiming to significantly improve patient outcomes.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 10","pages":"Pages 2860-2882"},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141705006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized Trial of Nitrate-Replete Beetroot Juice on Blood Pressure in Hypertensive Adults with ADPKD","authors":"Priyanka S. Sagar ,&nbsp;James Elhindi ,&nbsp;Katrina Chau ,&nbsp;David C. Harris ,&nbsp;Vincent Lee ,&nbsp;Kamal Sud ,&nbsp;Nikki Wong ,&nbsp;Gopala K. Rangan","doi":"10.1016/j.ekir.2024.07.017","DOIUrl":"10.1016/j.ekir.2024.07.017","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 10","pages":"Pages 3045-3048"},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141842265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CFAP47 is Implicated in X-Linked Polycystic Kidney Disease.","authors":"Takayasu Mori, Takuya Fujimaru, Chunyu Liu, Karynne Patterson, Kouhei Yamamoto, Takefumi Suzuki, Motoko Chiga, Akinari Sekine, Yoshifumi Ubara, Danny E Miller, Miranda P G Zalusky, Shintaro Mandai, Fumiaki Ando, Yutaro Mori, Hiroaki Kikuchi, Koichiro Susa, Jessica X Chong, Michael J Bamshad, Yue-Qiu Tan, Feng Zhang, Shinichi Uchida, Eisei Sohara","doi":"10.1016/j.ekir.2024.09.013","DOIUrl":"10.1016/j.ekir.2024.09.013","url":null,"abstract":"<p><strong>Introduction: </strong>Autosomal dominant polycystic kidney disease (ADPKD) is a well-described condition in which approximately 80% of all cases have a genetic explanation; and among sporadic cases without a family history, the genetic bases remain unclear in approximately 30% of cases. This study aimed to identify genes associated with polycystic kidney disease (PKD) in patients with sporadic cystic kidney disease in which a clear genetic change was not identified in established genes.</p><p><strong>Methods: </strong>A next-generation sequencing panel analyzed known genes related to kidney cysts in 118 sporadic cases, followed by whole-genome sequencing (WGS) on 47 unrelated individuals without identified candidate variants. Immunohistology examination was then conducted on both human kidney tissue and kidneys from CFAP47^-/Y mice.</p><p><strong>Results: </strong>Three male patients were found to have rare missense variants in the X-linked gene cilia and flagella-associated protein 47 (CFAP47), none of whom had a family history of the condition. CFAP47 was expressed in primary cilia of human kidney tubules, and knockout (KO) mice exhibited vacuolation of tubular cells and tubular dilation, providing evidence that CFAP47 is a causative gene involved in cyst formation.</p><p><strong>Conclusion: </strong>This discovery of CFAP47 as a newly identified gene associated with PKD, displaying X-linked inheritance, emphasizes the need for further cases to understand the role of CFAP47 in PKD.</p>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 12","pages":"3580-3591"},"PeriodicalIF":5.7,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2-Inhibition in Patients With Alport Syndrome.","authors":"Jan Boeckhaus, Daniel P Gale, James Simon, Jie Ding, Yanqin Zhang, Carsten Bergmann, A Neil Turner, Matthew Hall, John A Sayer, Shalabh Srivastava, Hee Gyung Kang, Agne Cerkauskaite-Kerpauskiene, Valentine Gillion, Kathleen J Claes, Bastian Krueger, Jonathan de Fallois, Ulrike Walden, Mira Choi, Markus Schueler, Roman-Ulrich Mueller, Polina Todorova, Bernd Hohenstein, Michael Zeisberg, Tim Friede, Bertrand Knebelmann, Jan Halbritter, Oliver Gross","doi":"10.1016/j.ekir.2024.09.014","DOIUrl":"10.1016/j.ekir.2024.09.014","url":null,"abstract":"<p><strong>Introduction: </strong>Large-scale trials showed positive outcomes of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in adults with chronic kidney disease (CKD). Whether the use of SGLT2i is safe and effective in patients with the common hereditary CKD Alport syndrome (AS) has not yet been investigated specifically in larger cohorts.</p><p><strong>Methods: </strong>This observational, multicenter, international study (NCT02378805) assessed 112 patients with AS after start of SGLT2i. The study's primary end point was change of albuminuria in albumin/g creatinine from the start of therapy.</p><p><strong>Results: </strong>Compared to randomized trials investigating the effect of SGLT2i in CKD, the adult patients in this study were younger (aged 38 ± 14 years) and had a better estimated glomerular filtration rate (eGFR, 63 ± 35 ml/min per 1.73 m²; <i>n</i> = 98). Maximum follow-up was 32 months. Compared to baseline, at the first 3 follow-up visits (months 1 to 3, 4 to 8, and 9 to 15) after initiation of SGLT2i therapy, a significant reduction of albuminuria in mg albumin/g creatinine (>30%) was observed. Mean loss of eGFR was 9 ± 12 ml/min per 1.73 m² almost 1 year after initiation of SGLT2i therapy (<i>n</i> = 35). At a total of 71 patient-years at risk, 0.24 adverse events (AEs) per patient-year on SGLT2i were reported.</p><p><strong>Conclusion: </strong>This study indicates that, additive to renin-angiotensin system (RAS)-inhibition (RASi), SGLT2i have the potential to reduce the amount of albuminuria in patients with AS. Future studies are needed to investigate the long-term effects of SGLT2i on CKD progression in patients with AS to assess whether the observed reduction in albuminuria translates to a delay in kidney failure (KF).</p>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 12","pages":"3490-3500"},"PeriodicalIF":5.7,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation.","authors":"Marion Cremoni, Maxime Teisseyre, Olivier Thaunat, Céline Fernandez, Christine Payre, Alan Moutou, Hadi Zarif, Vesna Brglez, Laetitia Albano, Valérie Moal, Georges Mourad, Emmanuel Morelon, Bruno Hurault de Ligny, Philippe Zaoui, Eric Rondeau, Nacera Ouali, Pierre Ronco, Bruno Moulin, Laura Braun-Parvez, Antoine Durrbach, Anne-Elisabeth Heng, Philippe Grimbert, Didier Ducloux, Gilles Blancho, Pierre Merville, Gabriel Choukroun, Yannick Le Meur, Cécile Vigneau, Christophe Mariat, Lionel Rostaing, Jean-François Subra, Jean-Luc Taupin, Gérard Lambeau, Vincent Esnault, Antoine Sicard, Barbara Seitz-Polski","doi":"10.1016/j.ekir.2024.09.012","DOIUrl":"10.1016/j.ekir.2024.09.012","url":null,"abstract":"<p><strong>Introduction: </strong>Membranous nephropathy can lead to end-stage kidney disease, for which kidney transplantation is the preferred therapy. However, the disease often relapses, which can impact allograft survival.</p><p><strong>Methods: </strong>We conducted a prospective multicenter study in France involving 72 patients with membranous nephropathy who were awaiting and then underwent kidney transplantation. In addition, we established a retrospective validation cohort of 65 patients. The primary objective was to evaluate the prognostic significance of pretransplant anti phospholipase A2 receptor 1 (PLA2R1) antibodies on the recurrence of membranous nephropathy. The study also assessed the incidence rate, time to onset, and risk factors for recurrence, as well as allograft outcome.</p><p><strong>Results: </strong>The prospective cohort showed a 26% cumulative incidence of membranous nephropathy recurrence after a median follow-up of 23.5 months. This was confirmed by a 28% cumulative incidence after a median follow-up of 67 months in the retrospective cohort. A strong association was found between the presence of anti-PLA2R1 antibodies prior to transplantation and the risk of disease recurrence (risk ratio = 5.9; 95% confidence interval [CI]: 2.3-15.7; <i>P</i> < 0.0001). These results were confirmed in the retrospective cohort. Monitoring of anti-PLA2R1 antibodies in the immediate posttransplant period is of limited value, because recurrence occurred early in the first 6 months (median delay of 5 [3-14] months) after transplantation despite decreasing antibody levels.</p><p><strong>Conclusion: </strong>The presence of anti-PLA2R1 antibodies prior to transplantation was a strong predictor of recurrence of allograft membranous nephropathy. An individualized immunomonitoring and management strategy for kidney transplant candidates with anti-PLA2R1-associated membranous nephropathy should be considered.</p>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"9 12","pages":"3427-3438"},"PeriodicalIF":5.7,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}